Allogene Therapeutics Inc

NASDAQ:ALLO 4:00:00 PM EDT

5.03

+0.01 (+0.20%)

4:48:22 PM EDT: $5.03 0.00 (0.00%)

Products

Allogene Therapeutics Announces Preclinical Findings Supporting Allo-605, First Anti-Bcma Turbocar T Cell Therapy

Published: 12/07/2020 16:21 GMT

Allogene Therapeutics Inc (ALLO) - Allogene Therapeutics Inc - Announced Preclinical Findings Supporting Allo-605, First Anti-bcma Turbocar T Cell Therapy.
Allogene Therapeutics Inc - Allo-605 Demonstrated Enhanced Killing of Multiple Myeloma Cells and Persistence Relative to Bcma Car T.
Allogene Therapeutics Inc - Investigational New Drug Application for Allo-605 Expected in First Half of 2021.